Forex

RBC Sees 117% Upside in Attovia Therapeutics Stock

Guavy AI Editorial Team Published August 31, 2026

Instruments

CAD

Analysts at Royal Bank Of Canada have assumed coverage of Attovia Therapeutics (NASDAQ:ATTO) and assigned an 'outperform' rating with a price target of $45.00.

This represents a potential upside of 117.39% from the stock's current price, which is $20.70 per share.

Other analysts have also weighed in on Attovia Therapeutics, with Leerink Partners and Morgan Stanley issuing 'outperform' ratings and Citigroup assigning a 'buy' rating.

S&P 500 Endures Hawkish Fed Speech Amid Strong Earnings

Forex just now

$40 Trillion Debt Pile Sparks Fears of 'Death Spiral' for US Dollar

Forex 1m ago

Warsh Signals Rate Hike Possible at September Meeting

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

Terms Privacy Policy